Progress in the Systemic Therapy of Urological Oncology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 May 2025 | Viewed by 1777

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
Interests: testicular cancer; prostate cancer; urothelial cancer; immunotherapy; de-escalation strategies; biomarkers; treatment resistance

Special Issue Information

Dear Colleagues,

Progress in the systemic therapy of urological oncology has been extraordinary in recent years. New treatments, such as immunotherapies, hormonal and targeted therapies, antibody-drug conjugates and radioligand therapies, have improved survival rates and quality of life for patients with various urological cancers. Additionally, precision medicine tools, utilising various platforms of molecular testing, have allowed for more personalised treatment plans. We are now entering an era of carefully crafting de-escalation and intensification approaches for metastatic disease, as well as intelligent early relapse detection and adjuvant therapy strategies. Our next generation clinical trials are biomarker-guided, such as minimal residual disease detection surrogates, that range from simple proteins (PSA in prostate cancer or PD-L1 expression in renal cancer), to microRNAs (miRNA-371 in testicular cancer) or ctDNA detection (urothelial cancer), or even radiomics (PSMA and other metabolic imaging in prostate cancer). This Special Issue invites papers on systemic therapies (e.g., chemotherapy, hormone therapy, immunotherapy, targeted therapy, radioligand therapies, novel therapeutics) in urological cancers.

Dr. Anna Patrikidou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • systemic therapy
  • urological oncology
  • chemotherapy
  • hormone therapy
  • immunotherapy
  • targeted therapy
  • radioligand therapy
  • antibody-drug conjugates
  • novel therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 2040 KiB  
Article
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
by Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, Naara Appel, Philippe Gonnet, Gesuino Angius, Petros Tsantoulis, Hendrick-Tobias Arkenau, Carlo Cattrini, Carlo Messina, Jean Zeghondy, Cristina Morelli, Yohann Loriot, Vincenzo Formica and Anna Patrikidouadd Show full author list remove Hide full author list
Cancers 2024, 16(8), 1465; https://doi.org/10.3390/cancers16081465 - 11 Apr 2024
Cited by 2 | Viewed by 1251
Abstract
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. Methods: Fifteen [...] Read more.
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free survival (PFS) in a development (D, n = 264) and a validation (V, n = 132) cohort of platinum-pretreated a/mUC pts receiving ICIs at L2 or further line. A nomogram and inflammatory prognostic index (U-IPI) were developed. The index was also tested in a control cohort of patients treated with chemotherapy only (C, n = 114). Results: The strongest predictors of OS were baseline platelet/lymphocyte (PLR) and neutrophil/lymphocyte (NLR) ratios, and lactate dehydrogenase (LDH), NLR, and albumin changes at 4 weeks. These were used to build the U-IPI, which can distinctly classify patients into good or poor response groups. The nomogram scoring is significant for PFS and OS (p < 0.001 in the D, V, and combined cohorts) for the immunotherapy (IO) cohort, but not for the control cohort. Conclusions: The lack of a baseline systemic inflammatory profile and the absence of early serum inflammatory biomarker changes are associated with significantly better outcomes on ICIs in a/mUC pts. The U-IPI is an easily applicable dynamic prognostic tool for PFS and OS, allowing for the early identification of a sub-group with dismal outcomes that would not benefit from ICIs, while distinguishing another that draws an important benefit. Full article
(This article belongs to the Special Issue Progress in the Systemic Therapy of Urological Oncology)
Show Figures

Figure 1

Back to TopTop